Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Impact of coffee on liver diseases: a systematic review.

Saab S, Mallam D, Cox GA 2nd, Tong MJ.

Liver Int. 2014 Apr;34(4):495-504. doi: 10.1111/liv.12304. Epub 2013 Sep 15. Review.

PMID:
24102757
2.

Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection?

Chen S, Teoh NC, Chitturi S, Farrell GC.

J Gastroenterol Hepatol. 2014 Mar;29(3):435-41. doi: 10.1111/jgh.12422. Review.

PMID:
24199670
3.

Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers.

Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, Zakouji H.

Int J Epidemiol. 1998 Jun;27(3):438-43.

PMID:
9698132
4.

[Coffee can be beneficial for patients with liver diseases].

Kjærgaard M, Thiele M, Krag A.

Ugeskr Laeger. 2014 Oct 20;176(43). pii: V04140209. Review. Danish.

PMID:
25353679
5.

Coffee and liver diseases.

Muriel P, Arauz J.

Fitoterapia. 2010 Jul;81(5):297-305. doi: 10.1016/j.fitote.2009.10.003. Epub 2009 Oct 13. Review.

PMID:
19825397
6.

Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.

Tokushige K, Hashimoto E, Kodama K.

J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:88-92. doi: 10.1111/jgh.12239. Review.

PMID:
24251711
7.

Coffee has hepatoprotective benefits in Brazilian patients with chronic hepatitis C even in lower daily consumption than in American and European populations.

Machado SR, Parise ER, Carvalho Ld.

Braz J Infect Dis. 2014 Mar-Apr;18(2):170-6. doi: 10.1016/j.bjid.2013.09.001. Epub 2013 Nov 22.

8.

Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis.

Kennedy OJ, Roderick P, Buchanan R, Fallowfield JA, Hayes PC, Parkes J.

BMJ Open. 2017 May 9;7(5):e013739. doi: 10.1136/bmjopen-2016-013739. Review.

9.

Coffee and liver health.

Morisco F, Lembo V, Mazzone G, Camera S, Caporaso N.

J Clin Gastroenterol. 2014 Nov-Dec;48 Suppl 1:S87-90. doi: 10.1097/MCG.0000000000000240. Review.

PMID:
25291138
11.

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A.

Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72.

12.

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis.

Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA.

Hepatology. 2012 Feb;55(2):429-36. doi: 10.1002/hep.24731. Epub 2011 Dec 22.

PMID:
21987293
13.

The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients.

Mathiesen UL, Franzén LE, Frydén A, Foberg U, Bodemar G.

Scand J Gastroenterol. 1999 Jan;34(1):85-91.

PMID:
10048738
14.

[Coffee as hepatoprotective factor].

Szántová M, Ďurkovičová Z.

Vnitr Lek. Winter 2016;62(12):990-997. Review. Czech.

PMID:
28139128
15.

Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis.

Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1413-1421.e1. doi: 10.1016/j.cgh.2013.04.039. Epub 2013 May 6.

PMID:
23660416
16.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

17.

The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition.

Aleksandrova K, Bamia C, Drogan D, Lagiou P, Trichopoulou A, Jenab M, Fedirko V, Romieu I, Bueno-de-Mesquita HB, Pischon T, Tsilidis K, Overvad K, Tjønneland A, Bouton-Ruault MC, Dossus L, Racine A, Kaaks R, Kühn T, Tsironis C, Papatesta EM, Saitakis G, Palli D, Panico S, Grioni S, Tumino R, Vineis P, Peeters PH, Weiderpass E, Lukic M, Braaten T, Quirós JR, Luján-Barroso L, Sánchez MJ, Chilarque MD, Ardanas E, Dorronsoro M, Nilsson LM, Sund M, Wallström P, Ohlsson B, Bradbury KE, Khaw KT, Wareham N, Stepien M, Duarte-Salles T, Assi N, Murphy N, Gunter MJ, Riboli E, Boeing H, Trichopoulos D.

Am J Clin Nutr. 2015 Dec;102(6):1498-508. doi: 10.3945/ajcn.115.116095. Epub 2015 Nov 11.

18.

Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study.

Leung WW, Ho SC, Chan HL, Wong V, Yeo W, Mok TS.

J Epidemiol Community Health. 2011 Jun;65(6):556-8. doi: 10.1136/jech.2009.104125. Epub 2010 Aug 6.

PMID:
20693491
19.

Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010.

Xiao Q, Sinha R, Graubard BI, Freedman ND.

Hepatology. 2014 Dec;60(6):2091-8. doi: 10.1002/hep.27367. Epub 2014 Oct 30.

20.

Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.

Marventano S, Salomone F, Godos J, Pluchinotta F, Del Rio D, Mistretta A, Grosso G.

Clin Nutr. 2016 Dec;35(6):1269-1281. doi: 10.1016/j.clnu.2016.03.012. Epub 2016 Mar 30. Review.

PMID:
27060021

Supplemental Content

Support Center